The urgent need for clinical research reform to permit faster, less expensive access to new therapies for lethal diseases

David J. Stewart, Gerald Batist, Hagop M. Kantarjian, John Peter Bradford, Joan H. Schiller, Razelle Kurzrock

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

High costs of complying with drug development regulations slow progress and contribute to high drug prices and, hence, mounting health care costs. If it is exorbitantly expensive to bring new therapies to approval, fewer agents can be developed with available resources, impeding the emergence of urgently needed treatments and escalating prices by limiting competition. Excessive regulation produces numerous speed bumps on the road to drug authorization. Although an explosion of knowledge could fuel rapid advances, progress has been slowed worldwide by inefficient regulatory and clinical research systems that limit access to therapies that prolong life and relieve suffering. We must replace current compliance-centered regulation (appropriate for nonlethal diseases like acne) with "progress-centered regulation" in lethal diseases, where the overarching objective must be rapid, inexpensive development of effective new therapies. We need to (i) reduce expensive, time-consuming preclinical toxicology and pharmacology assessments, which add little value; (ii) revamp the clinical trial approval process to make it fast and efficient; (iii) permit immediate multiple-site trial activation when an eligible patient is identified ("just-in-time" activation); (iv) reduce the requirement for excessive, low-value documentation; (v) replace this excessive documentation with sensible postmarketing surveillance; (vi) develop pragmatic investigator accreditation; (vii) where it is to the benefit of the patient, permit investigators latitude in deviating from protocols, without requiring approved amendments; (viii) confirm the value of predictive biomarkers before requiring the high costs of IDE/CLIA compliance; and (ix) approve agents based on high phase I-II response rates in defined subpopulations, rather than mandating expensive, time-consuming phase III trials.

Original languageEnglish (US)
Pages (from-to)4561-4568
Number of pages8
JournalClinical Cancer Research
Volume21
Issue number20
DOIs
StatePublished - Oct 15 2015

Fingerprint

Research
Documentation
Compliance
Research Personnel
Costs and Cost Analysis
Explosions
Accreditation
Drug and Narcotic Control
Acne Vulgaris
Therapeutics
Psychological Stress
Pharmaceutical Preparations
Health Care Costs
Toxicology
Biomarkers
Clinical Trials
Pharmacology

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Stewart, D. J., Batist, G., Kantarjian, H. M., Bradford, J. P., Schiller, J. H., & Kurzrock, R. (2015). The urgent need for clinical research reform to permit faster, less expensive access to new therapies for lethal diseases. Clinical Cancer Research, 21(20), 4561-4568. https://doi.org/10.1158/1078-0432.CCR-14-3246

The urgent need for clinical research reform to permit faster, less expensive access to new therapies for lethal diseases. / Stewart, David J.; Batist, Gerald; Kantarjian, Hagop M.; Bradford, John Peter; Schiller, Joan H.; Kurzrock, Razelle.

In: Clinical Cancer Research, Vol. 21, No. 20, 15.10.2015, p. 4561-4568.

Research output: Contribution to journalArticle

Stewart, David J. ; Batist, Gerald ; Kantarjian, Hagop M. ; Bradford, John Peter ; Schiller, Joan H. ; Kurzrock, Razelle. / The urgent need for clinical research reform to permit faster, less expensive access to new therapies for lethal diseases. In: Clinical Cancer Research. 2015 ; Vol. 21, No. 20. pp. 4561-4568.
@article{270385987f7c4a83bd324c688a4a6b5d,
title = "The urgent need for clinical research reform to permit faster, less expensive access to new therapies for lethal diseases",
abstract = "High costs of complying with drug development regulations slow progress and contribute to high drug prices and, hence, mounting health care costs. If it is exorbitantly expensive to bring new therapies to approval, fewer agents can be developed with available resources, impeding the emergence of urgently needed treatments and escalating prices by limiting competition. Excessive regulation produces numerous speed bumps on the road to drug authorization. Although an explosion of knowledge could fuel rapid advances, progress has been slowed worldwide by inefficient regulatory and clinical research systems that limit access to therapies that prolong life and relieve suffering. We must replace current compliance-centered regulation (appropriate for nonlethal diseases like acne) with {"}progress-centered regulation{"} in lethal diseases, where the overarching objective must be rapid, inexpensive development of effective new therapies. We need to (i) reduce expensive, time-consuming preclinical toxicology and pharmacology assessments, which add little value; (ii) revamp the clinical trial approval process to make it fast and efficient; (iii) permit immediate multiple-site trial activation when an eligible patient is identified ({"}just-in-time{"} activation); (iv) reduce the requirement for excessive, low-value documentation; (v) replace this excessive documentation with sensible postmarketing surveillance; (vi) develop pragmatic investigator accreditation; (vii) where it is to the benefit of the patient, permit investigators latitude in deviating from protocols, without requiring approved amendments; (viii) confirm the value of predictive biomarkers before requiring the high costs of IDE/CLIA compliance; and (ix) approve agents based on high phase I-II response rates in defined subpopulations, rather than mandating expensive, time-consuming phase III trials.",
author = "Stewart, {David J.} and Gerald Batist and Kantarjian, {Hagop M.} and Bradford, {John Peter} and Schiller, {Joan H.} and Razelle Kurzrock",
year = "2015",
month = "10",
day = "15",
doi = "10.1158/1078-0432.CCR-14-3246",
language = "English (US)",
volume = "21",
pages = "4561--4568",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - The urgent need for clinical research reform to permit faster, less expensive access to new therapies for lethal diseases

AU - Stewart, David J.

AU - Batist, Gerald

AU - Kantarjian, Hagop M.

AU - Bradford, John Peter

AU - Schiller, Joan H.

AU - Kurzrock, Razelle

PY - 2015/10/15

Y1 - 2015/10/15

N2 - High costs of complying with drug development regulations slow progress and contribute to high drug prices and, hence, mounting health care costs. If it is exorbitantly expensive to bring new therapies to approval, fewer agents can be developed with available resources, impeding the emergence of urgently needed treatments and escalating prices by limiting competition. Excessive regulation produces numerous speed bumps on the road to drug authorization. Although an explosion of knowledge could fuel rapid advances, progress has been slowed worldwide by inefficient regulatory and clinical research systems that limit access to therapies that prolong life and relieve suffering. We must replace current compliance-centered regulation (appropriate for nonlethal diseases like acne) with "progress-centered regulation" in lethal diseases, where the overarching objective must be rapid, inexpensive development of effective new therapies. We need to (i) reduce expensive, time-consuming preclinical toxicology and pharmacology assessments, which add little value; (ii) revamp the clinical trial approval process to make it fast and efficient; (iii) permit immediate multiple-site trial activation when an eligible patient is identified ("just-in-time" activation); (iv) reduce the requirement for excessive, low-value documentation; (v) replace this excessive documentation with sensible postmarketing surveillance; (vi) develop pragmatic investigator accreditation; (vii) where it is to the benefit of the patient, permit investigators latitude in deviating from protocols, without requiring approved amendments; (viii) confirm the value of predictive biomarkers before requiring the high costs of IDE/CLIA compliance; and (ix) approve agents based on high phase I-II response rates in defined subpopulations, rather than mandating expensive, time-consuming phase III trials.

AB - High costs of complying with drug development regulations slow progress and contribute to high drug prices and, hence, mounting health care costs. If it is exorbitantly expensive to bring new therapies to approval, fewer agents can be developed with available resources, impeding the emergence of urgently needed treatments and escalating prices by limiting competition. Excessive regulation produces numerous speed bumps on the road to drug authorization. Although an explosion of knowledge could fuel rapid advances, progress has been slowed worldwide by inefficient regulatory and clinical research systems that limit access to therapies that prolong life and relieve suffering. We must replace current compliance-centered regulation (appropriate for nonlethal diseases like acne) with "progress-centered regulation" in lethal diseases, where the overarching objective must be rapid, inexpensive development of effective new therapies. We need to (i) reduce expensive, time-consuming preclinical toxicology and pharmacology assessments, which add little value; (ii) revamp the clinical trial approval process to make it fast and efficient; (iii) permit immediate multiple-site trial activation when an eligible patient is identified ("just-in-time" activation); (iv) reduce the requirement for excessive, low-value documentation; (v) replace this excessive documentation with sensible postmarketing surveillance; (vi) develop pragmatic investigator accreditation; (vii) where it is to the benefit of the patient, permit investigators latitude in deviating from protocols, without requiring approved amendments; (viii) confirm the value of predictive biomarkers before requiring the high costs of IDE/CLIA compliance; and (ix) approve agents based on high phase I-II response rates in defined subpopulations, rather than mandating expensive, time-consuming phase III trials.

UR - http://www.scopus.com/inward/record.url?scp=84945544300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945544300&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-14-3246

DO - 10.1158/1078-0432.CCR-14-3246

M3 - Article

C2 - 26473192

AN - SCOPUS:84945544300

VL - 21

SP - 4561

EP - 4568

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 20

ER -